Carisma Therapeutics News

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting 2024

PR NewswireNov 17 07:30 ET

Carisma Therapeutics Is Maintained at Buy by D. Boral Capital

Dow JonesNov 11 17:20 ET · Ratings

Carisma Therapeutics Price Target Maintained With a $24.00/Share by D. Boral Capital

Dow JonesNov 11 17:20 ET · Ratings

Optimistic Buy Rating for Carisma Therapeutics Amid Promising CAR-Myeloid Developments and Strong Financial Standing

TipRanksNov 11 01:15 ET · Ratings

Evercore Maintains Carisma Therapeutics(CARM.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsNov 8 09:38 ET · Ratings

Evercore ISI Remains a Buy on Carisma Therapeutics (CARM)

TipRanksNov 8 09:19 ET · Ratings

Carisma Unveils Pre-Clinical Data On Anti-GPC3 In Vivo CAR-M Therapy For Hepatocellular Carcinoma Developed In Collaboration With Moderna

BenzingaNov 8 07:37 ET

Carisma Therapeutics Reports Data From Its CAR-M Therapy

TipRanksNov 8 07:35 ET

Express News | Carisma Unveils Promising Pre-Clinical Data on Anti-Gpc3 in Vivo Car-M Therapy for Hepatocellular Carcinoma

ReutersNov 8 07:30 ET

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

PR NewswireNov 8 07:30 ET

Express News | EF Hutton Maintains Buy on CARISMA Therapeutics, Maintains $24 Price Target

BenzingaNov 7 08:32 ET

Express News | CARISMA Therapeutics Q3 2024 GAAP EPS $(0.31) Misses $(0.24) Estimate, Sales $3.38M Miss $5.47M Estimate

BenzingaNov 7 07:55 ET

Carisma Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 7 07:43 ET · Announcements

Carisma Therapeutics | 8-K: Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

SECNov 7 07:38 ET

Carisma Therapeutics 3Q Loss/Shr 31c >CARM

Dow JonesNov 7 07:37 ET

Express News | Carisma Therapeutics Inc: Cash & Cash Equivalents of $26.9 Million Expected to Fund Co Into Q3 of 2025

ReutersNov 7 07:31 ET

Express News | Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

ReutersNov 7 07:30 ET

Express News | Carisma Therapeutics Q3 Net Income USD -12.702 Million

ReutersNov 7 07:30 ET

Press Release: Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Dow JonesNov 7 07:30 ET

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

PR NewswireNov 5 09:05 ET